Fulton Bank N.A. bought a new stake in argenx SE (NASDAQ:ARGX – Get Rating) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund bought 549 shares of the company’s stock, valued at approximately $208,000.
Several other institutional investors also recently bought and sold shares of ARGX. Steward Partners Investment Advisory LLC grew its position in shares of argenx by 126.0% during the first quarter. Steward Partners Investment Advisory LLC now owns 174 shares of the company’s stock worth $55,000 after buying an additional 97 shares in the last quarter. Ensign Peak Advisors Inc grew its position in shares of argenx by 96.5% during the fourth quarter. Ensign Peak Advisors Inc now owns 18,520 shares of the company’s stock worth $6,485,000 after buying an additional 9,097 shares in the last quarter. Envestnet Asset Management Inc. grew its position in shares of argenx by 68.6% during the first quarter. Envestnet Asset Management Inc. now owns 13,012 shares of the company’s stock worth $4,103,000 after buying an additional 5,294 shares in the last quarter. BNP Paribas Arbitrage SA acquired a new position in shares of argenx during the fourth quarter worth about $535,000. Finally, Laurel Wealth Advisors Inc. acquired a new position in shares of argenx during the fourth quarter worth about $231,000. 59.75% of the stock is owned by institutional investors and hedge funds.
argenx Stock Performance
NASDAQ:ARGX opened at $373.26 on Monday. The stock has a fifty day moving average price of $373.64 and a two-hundred day moving average price of $338.56. The stock has a market capitalization of $20.55 billion, a price-to-earnings ratio of -21.54 and a beta of 0.83. argenx SE has a 1 year low of $249.50 and a 1 year high of $403.77.
Analysts Set New Price Targets
A number of brokerages have recently commented on ARGX. Piper Sandler boosted their price objective on argenx from $450.00 to $465.00 and gave the stock an “overweight” rating in a research report on Friday, August 26th. Robert W. Baird reaffirmed a “downgrade” rating on shares of argenx in a report on Friday, July 29th. JPMorgan Chase & Co. upped their price target on argenx from €390.00 ($397.96) to €430.00 ($438.78) and gave the company an “overweight” rating in a report on Thursday, July 14th. Stifel Nicolaus upped their price target on argenx from $460.00 to $471.00 in a report on Thursday, July 28th. Finally, Morgan Stanley upped their price target on argenx from $375.00 to $401.00 and gave the company an “overweight” rating in a report on Friday, July 29th. One investment analyst has rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $397.50.
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study.
- Get a free copy of the StockNews.com research report on argenx (ARGX)
- Kroger’s is Your One-Stop Consumer Staples Stock
- Adobe Perfects the Art of the Faceplant for Investors
- Tax Credits are the Incentives in the Inflation Reduction Act
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.